DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
20,400
-50 (-0.24%)
Feb 27, 2026, 3:30 PM KST
27.50%
Market Cap 912.67B
Revenue (ttm) 894.93B
Net Income (ttm) 60.50B
Shares Out 44.74M
EPS (ttm) 1,358.99
PE Ratio 15.01
Forward PE 11.74
Dividend 200.00 (0.98%)
Ex-Dividend Date Dec 29, 2025
Volume 320,388
Average Volume 425,742
Open 20,550
Previous Close 20,450
Day's Range 19,990 - 20,750
52-Week Range 14,470 - 22,500
Beta 0.25
RSI 60.49
Earnings Date Mar 11, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,233
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.

Financial Statements

News

There is no news available yet.